Woodruff, Matthew C. http://orcid.org/0000-0002-5252-7539
Nguyen, Doan C. http://orcid.org/0000-0002-5389-6731
Faliti, Caterina E.
Saini, Ankur Singh
Lee, F. Eun-Hyung
Sanz, Ignacio http://orcid.org/0000-0003-4182-587X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA260563-01)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (P01-AI125180-01)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R37-AI049660, P01-AI125180-01, 1R01AI12125, 1U01AI141993)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
First Online: 8 April 2022
Competing interests
: F.E.-H.-L. is the founder of MicroB-plex, Inc. and has patents for the MENSA technology, and grants from the Bill and Melinda Gates Foundation and Genentech. F.E.-H.-L., D.C.N. and I.S. have patents for the PCSS. The authors collaborated with Exagen, Inc. to provide clinical autoreactivity testing in several COVID-19-related studies.
Free to read: This content has been made available to all.